MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41409-025-02605-2

Медицинская библиотека · Bone marrow transplantation · 2025

Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxis.

Chiurlo Matteo, Galli Laura, Farina Francesca, Acerbis Andrea, Mori Giovanni, Xue Elisabetta, Clerici Daniela, Mastaglio Sara, Piemontese Simona, Lupo Stanghellini Maria T, Ripa Marco, Tassan Din Chiara, Corti Consuelo, Peccatori Jacopo, Scarpellini Paolo, Castagna Antonella, Ciceri Fabio, Greco Raffaella, Oltolini Chiara

СтатьяПеревод в очереди

Аннотация

Incidence of breakthrough proven-probable invasive fungal infections (b-PP-IFIs) in allogeneic haematopoietic cell transplant recipients (allo-HCT-r) receiving mould-active prophylaxis (MAP) and post-transplant cyclophosphamide (PT-Cy) is largely unknown. Retrospective study on allo-HCT-r, classified at high-risk for IFIs whether ≥1 of the following conditions was met: 1] active disease; 2] cord-blood; 3] previous transplant; 4] acute graft-versus-host-disease (a-GVHD) grade≥3; 5] mismatched-related or unrelated donor with neutropenia before transplant or grade-2 a-GVHD or Cytomegalovirus infection. Objectives were to estimate cumulative incidence function (CIF) of b-PP-IFIs, evaluate infection-related mortality (IRM) and predictive factors of b-PP-IFIs. Overall, 473 allo-HCT-r (n = 286 posaconazole, n = 187 voriconazole) were analysed: 64.7% were at high-risk, 81.6% received PT-Cy. Fifteen b-PP-IFIs occurred: 14/306 in high-risk, 1/167 in non-high-risk group. CIF of b-PP-IFIs in high-risk group was 2.0% (95%CI = 0.8-4.1%) at 30-day and 5.1% (95%CI = 2.9-8.2%) at 1-year post-transplant. The 1-year CIF of IRM was higher in allo-HCT-r with b-PP-IFIs compared to those without [46.7% (95%CI = 19.6-70%) vs. 8.2% (95%CI = 5.3-9.2%), Gray's test: p < 0.001]. In allo-HCT-r receiving PT-Cy, neutropenia before transplant [sHR 7.54 (95%CI = 1.81-31.43)] and chronic myeloproliferative disorders versus AML/MDS [sHR 7.72 (95%CI = 1.68-35.42)] increased risk of b-PP-IFIs, while donor type did not. MAP effectively prevented IFIs. PT-Cy conferred a comparable risk of b-PP-IFIs in matched compared to mismatched-transplants.

Для цитирования: Chiurlo Matteo, Galli Laura, Farina Francesca, Acerbis Andrea, Mori Giovanni, Xue Elisabetta, Clerici Daniela, Mastaglio Sara, Piemontese Simona, Lupo Stanghellini Maria T, Ripa Marco, Tassan Din Chiara, Corti Consuelo, Peccatori Jacopo, Scarpellini Paolo, Castagna Antonella, Ciceri Fabio, Greco Raffaella, Oltolini Chiara. Risk stratification and impact of donor type on breakthrough invasive fungal infections in haematopoietic cell transplant with post-transplant cyclophosphamide and mould-active prophylaxis.. Bone marrow transplantation. 2025. DOI: 10.1038/s41409-025-02605-2.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.